Neuroendocrine cell hyperplasia of infancy – Diagnostics – Overview of Information and Clinical Research

Neuroendocrine cell hyperplasia of infancy (NEHI) is a rare lung condition that primarily affects very young children, causing persistent breathing difficulties and low oxygen levels. While the condition was only first described in 2005, understanding when and how to diagnose it can make a crucial difference in managing symptoms and supporting affected infants through their early years.

Introduction: Who Should Undergo Diagnostics

Diagnostic testing for neuroendocrine cell hyperplasia of infancy becomes necessary when infants show persistent breathing problems that don’t improve with typical treatments. Parents and doctors should consider seeking these specialized diagnostics when an infant displays rapid breathing, also called tachypnea, along with difficulty breathing and unusually low oxygen levels in the blood, a condition known as hypoxemia.^[1]

The condition typically appears during the first months to year of life, with most cases occurring around three months of age. Most affected babies are born at full term, although there has been one documented case in a premature infant.^[3] It’s particularly important to seek diagnostic evaluation when breathing difficulties persist despite treatment approaches that would normally work for more common childhood respiratory conditions like asthma or respiratory infections.

One of the challenging aspects of NEHI is that its symptoms can closely resemble other, more common lung diseases of childhood. Many children are initially thought to have asthma or prolonged respiratory infections because the symptoms overlap significantly. However, a key indicator that something different may be occurring is when children fail to respond to asthma treatments and corticosteroids, which would typically help with asthma or inflammation-related breathing problems.^[1]

When a doctor examines an infant with NEHI using a stethoscope, they will typically hear crackling sounds, called crackles, in the lungs. Some children may also wheeze, though this is not as characteristic of the condition. The infant may also show visible signs of struggling to breathe, including retractions, where the skin pulls in around the ribs and neck with each breath.^[2]

⚠️ Important

Because NEHI can subtly masquerade as more common lung diseases during the first year of life, many cases go underdiagnosed. If your infant has persistent breathing difficulties that don’t improve with standard treatments, it’s important to discuss the possibility of childhood interstitial lung disease with your healthcare provider.

Diagnostic Methods

Diagnosing NEHI requires a systematic approach involving multiple types of tests. The process begins with efforts to rule out other conditions that might cause similar symptoms, as accurate diagnosis is crucial for appropriate clinical management.^[3]

Laboratory Tests

The diagnostic journey typically starts with laboratory work designed to exclude other possible causes of respiratory symptoms. Doctors will often perform tests to rule out conditions like cystic fibrosis, which can cause breathing problems in infants, and immunodeficiency disorders, which might make children more susceptible to respiratory issues. These lab tests help narrow down the possibilities and point toward or away from NEHI as the underlying cause.^[1]

High-Resolution CT Scan

A high-resolution computed tomography scan, or CT scan, of the lungs has become one of the most useful tools in diagnosing NEHI. This imaging test creates detailed pictures of the lungs and reveals characteristic patterns that strongly suggest NEHI. The CT scan typically shows what doctors call “ground glass opacities,” which are hazy areas that look like frosted glass on the scan.^[1]

Another distinctive feature visible on CT scans is a mosaic pattern in the lungs. This pattern occurs because different areas of the lungs are inflated to different extents—some areas appear overinflated while others appear underinflated. This uneven inflation creates a patchwork appearance that is characteristic of NEHI. The CT scan is considered a major imaging approach for assisting in diagnosis, and these typical findings of ground glass opacities combined with air trapping are key characteristics that help identify the condition.^[3]

Bronchoscopy with Bronchoalveolar Lavage

A bronchoscopy with bronchoalveolar lavage, often abbreviated as BAL, is another common procedure in the diagnostic process. During this test, a doctor inserts a thin, flexible tube with a camera through the nose or mouth, down the windpipe, and into the lungs. This allows them to look directly at the airways and collect fluid samples from the lungs.^[1]

The fluid collected during this procedure can be examined for signs of infection, inflammation, and evidence that food or liquid might be getting into the lungs, a problem called aspiration. By analyzing this fluid, doctors can check for various issues that might be causing breathing problems and help distinguish NEHI from other conditions.^[1]

Infant Pulmonary Function Test

The Infant Pulmonary Function Test, or infant PFT, has become increasingly important in diagnosing NEHI. This test measures how well the infant’s lungs are working and typically shows air trapping in the lungs of NEHI patients, along with other characteristic results. However, this test isn’t always available because it requires specialized equipment that not all medical centers have.^[1]

Despite its limitations in availability, when an infant PFT can be performed, it provides valuable information about lung function that helps support the diagnosis. The test results help doctors understand the extent of the breathing difficulties and how air is moving in and out of the lungs.

Diagnosis Without Biopsy: NEHI Syndrome

One of the important advances in diagnosing NEHI is that if all the diagnostic tests described above show results characteristic of the condition, a child may receive a diagnosis of “NEHI Syndrome” without needing a lung biopsy. This is significant because biopsies are invasive procedures that carry some risk, especially in young infants.^[1]

However, this approach only works when all the test results and symptoms clearly point to NEHI. If any of the findings or symptoms are not typical, or if there’s uncertainty about the diagnosis, doctors may need to proceed with a lung biopsy to confirm the condition definitively.

Lung Biopsy

When test results are unclear or atypical, a lung biopsy becomes the only way to conclusively confirm a NEHI diagnosis. During a biopsy, doctors remove a small piece of lung tissue to examine under a microscope. This tissue sample can reveal important details about what’s happening in the lungs at a cellular level.^[1]

The biopsy tissue from NEHI patients typically shows little or no inflammation, which helps distinguish it from other lung conditions that involve significant inflammation. More importantly, when the tissue is treated with a special stain called bombesin stain, it reveals an abnormally increased number of pulmonary neuroendocrine cells, or PNECs, within the small airways.^[1]

These PNECs are cells normally present in the lining of the airways, either alone or in small clusters called neuroepithelial bodies or NEBs. Scientists believe these cells play a role in lung development. In healthy lungs, these cells are present in normal numbers, but in NEHI, the number of PNECs and NEBs in the airways is always significantly increased. This increase in neuroendocrine cells is what gives the condition its name, and the finding of this hyperplasia, or excessive growth of these cells, confirms the diagnosis.^[1]

Diagnostics for Clinical Trial Qualification

The sources provided do not contain specific information about diagnostic criteria or tests used as standard requirements for enrolling patients in clinical trials for NEHI. The general diagnostic methods described above—including CT scans showing characteristic patterns, bronchoscopy findings, pulmonary function tests, and potentially lung biopsy results—would likely form the basis for confirming a NEHI diagnosis in any clinical research setting. However, specific trial enrollment criteria would depend on the particular study protocols, which are not detailed in the available sources.

Prognosis and Survival Rate

Prognosis

The prognosis for children with neuroendocrine cell hyperplasia of infancy is generally positive, with most children showing improvement over time. The condition is considered non-progressive, meaning it doesn’t typically worsen as children grow. An important aspect of the disease’s natural course is that neuroendocrine cells do not multiply or increase in size as the child develops, but the lungs themselves continue to grow normally.^[6]

This growth pattern means that as the lungs expand during childhood development, the same number of abnormal neuroendocrine cells becomes proportionally less significant. In other words, while affected children will always have the same number of neuroendocrine cells they were born with, those cells have less effect on lung function as the lungs grow larger. This biological reality underlies the generally favorable outlook for these patients.^[6]

Most children with NEHI gradually decrease their need for oxygen supplementation over time. Some infants require oxygen around the clock initially, while others only need it at night or during periods of illness. As children grow, many eventually outgrow the need for supplemental oxygen entirely, typically within two to seven years. This improvement reflects the relative decrease in the impact of the excess neuroendocrine cells as lung capacity increases.^[1]^[6]

However, the condition does carry some risks during early childhood. Common colds and flu can be more severe in NEHI patients than in healthy children, so avoiding exposure to respiratory infections remains important throughout the most vulnerable years. In severe cases, there is a risk of permanent lung damage and even death from severe tachypnea, though these outcomes are less common with appropriate supportive care.^[1]^[6]

One complication that frequently affects children with NEHI is failure to thrive, which means poor weight gain and growth. This occurs because the labored breathing characteristic of NEHI uses significantly more calories than normal breathing. Additionally, many NEHI children experience gastroesophageal reflux, commonly known as GERD, which can further interfere with adequate nutrition. These nutritional challenges can affect overall health and development during the critical early years.^[1]

Survival Rate

The sources provided do not contain specific survival statistics or percentages for patients with neuroendocrine cell hyperplasia of infancy. While the condition is described as carrying some mortality risk in severe cases, particularly from severe tachypnea, specific survival rates or percentages of patients surviving after particular time frames are not documented in the available information.

#1 Clinical Trials Search in Europe